- $21.02m
- -$15.06m
- $2.05m
- 28
- 25
- 47
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.77 | ||
| Price to Tang. Book | 0.77 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.25 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -108.94% | ||
| Return on Equity | -78.34% | ||
| Operating Margin | -1785.18% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.94 | 0.17 | 0.23 | 1.52 | 2.05 | 8.81 | 8.64 | -30.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.
Directors
- Richard Hawkins CHM (72)
- John McKew PRE (57)
- Lori Lawley CFO (37)
- Bradley Powers GCN (42)
- David Karpf OTH (61)
- Thomas Raffin LED (73)
- An van Es-Johansson IND (61)
- Chad Johnson IND (42)
- Kevin Lalande IND (48)
- Joseph McCracken IND (67)
- Lota Zoth IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 4th, 1999
- Public Since
- November 11th, 2011
- No. of Shareholders
- 66
- No. of Employees
- 33
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 8,116,488
- Address
- 4200 MARATHON BLVD., SUITE 200, AUSTIN, 78756
- Web
- https://lumos-pharma.com/
- Phone
- +1 5122152630
- Auditors
- KPMG LLP
Upcoming Events for LUMO
Lumos Pharma Inc Annual Shareholders Meeting
Lumos Pharma Inc Annual Shareholders Meeting
Q2 2024 Lumos Pharma Inc Earnings Release
Similar to LUMO
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Lumos Pharma share price?
As of Today at 19:13 UTC, shares in Lumos Pharma are trading at $2.59. This share price information is delayed by 15 minutes.
How has the Lumos Pharma share price performed this year?
Shares in Lumos Pharma last closed at $2.59 and the price had moved by -15.36% over the past 365 days. In terms of relative price strength the Lumos Pharma share price has underperformed the S&P500 Index by -29.57% over the past year.
What are the analyst and broker recommendations for Lumos Pharma?
The overall consensus recommendation for Lumos Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Lumos Pharma dividend yield?
Lumos Pharma does not currently pay a dividend.
Does Lumos Pharma pay a dividend?
Lumos Pharma does not currently pay a dividend.
When does Lumos Pharma next pay dividends?
Lumos Pharma does not currently pay a dividend.
How do I buy Lumos Pharma shares?
To buy shares in Lumos Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lumos Pharma?
As of the previous close price of $2.59, shares in Lumos Pharma had a market capitalisation of $21.02m.
Where are Lumos Pharma shares listed?
Here are the trading details for Lumos Pharma:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: LUMO
What kind of share is Lumos Pharma?
Based on an overall assessment of its quality, value and momentum Lumos Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lumos Pharma share price forecast for 2024?
The analyst consensus target price for shares in Lumos Pharma is $22.50. That is 768.73% above the last closing price of $2.59.
Analysts covering Lumos Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$2.81 for the next financial year.
What is the trend in the Lumos Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lumos Pharma. Over the past six months, its share price has underperformed the S&P500 Index by -39.59%.
As of the last closing price of $2.59, shares in Lumos Pharma were trading -17.17% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lumos Pharma PE Ratio?
The Lumos Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.59.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lumos Pharma?
Lumos Pharma's management team is headed by:
- Richard Hawkins - CHM
- John McKew - PRE
- Lori Lawley - CFO
- Bradley Powers - GCN
- David Karpf - OTH
- Thomas Raffin - LED
- An van Es-Johansson - IND
- Chad Johnson - IND
- Kevin Lalande - IND
- Joseph McCracken - IND
- Lota Zoth - IND